Advanced ovarian cancer Pipeline

"DelveInsight’s, “Advanced Ovarian Cancer Pipeline Insight, 2026” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Advanced Ovarian Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Advanced Ovarian Cancer Understanding

Advanced Ovarian Cancer Overview

Advanced Ovarian Cancer is the leading cause of death in women diagnosed with gynecological cancers. It is also the fifth most frequent cause of death in women, in general. Most of the cases are diagnosed at an advanced stage, which leads to poor outcomes of this disease. The existing screening tests have a low predictive value contributing further to this misery. Detailed gynecological evaluation along with transvaginal ultrasound and laboratory marker like cancer antigen-125 (CA-125) assay are the key early detection strategies which have shown no significant beneficial effect in the morbidity or mortality of this cancer.  Advanced Ovarian Cancer can present with a range of symptoms, including persistent abdominal pain, bloating, changes in bowel or urinary habits, and unexplained weight loss. Patients may experience fatigue, difficulty eating, back pain, or pain during sex. As the cancer spreads, additional signs may include fluid buildup in the abdomen or around the lungs, bowel obstruction, leg swelling, or new lumps. Skin changes, vaginal discharge, and abnormal bleeding may also occur, reflecting the progression of the disease.

The pathophysiology of Advanced Ovarian Cancer involves the uncontrolled growth and spread of malignant ovarian cells. These cancer cells often invade surrounding tissues and organs, leading to the formation of secondary tumors. As the cancer progresses, it can cause fluid accumulation (ascites), obstruct normal organ function, and spread to distant sites such as the lungs or abdomen, disrupting normal physiological processes. The tumor's ability to resist treatment and recur further complicates disease management. The cancer cells can also secrete various growth factors that promote angiogenesis, enabling tumor growth and metastasis. Additionally, the immune system's ability to detect and fight the cancer cells is often compromised, allowing the tumor to persist and spread despite treatment efforts.
In patients with a high degree of clinical suspicion, radiological imaging including transvaginal ultrasonography (TVUS, highly sensitive and preferred) and/or abdominal and pelvic ultrasonography is done. It gives a fair idea about the size, location, and complexity of the ovarian mass. For defining tumor extension, further imaging with chest and abdomen pelvis CT scan, MRI, and/or PET scan can be done.  Measurement of CA-125 levels is usually done in adjunction with the imaging. CA-125 is elevated in most of the epithelial ovarian cancers overall, but only half of the early stage epithelial ovarian cancers.

For many years the optimal treatment for women with advanced ovarian cancer has been surgical cytoreduction followed by intravenous platinum and taxane chemotherapy on an every three-week schedule. Recent clinical trials suggest that new treatment paradigms with different routes, dosing schedules and addition of targeted biologic therapies are replacing this old standard. In addition, new research suggests that ovarian, fallopian tube and peritoneal cancers may arise from a similar precursor, but histologic variants may require different treatment strategies.

Advanced Ovarian Cancer- Pipeline Insight, 2026"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Advanced Ovarian Cancer pipeline landscape is provided which includes the disease overview and Advanced Ovarian Cancer treatment guidelines. The assessment part of the report embraces, in depth Advanced Ovarian Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Ovarian Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Discover the latest Advanced Ovarian Cancer pipeline insights, emerging therapies, and clinical advancements shaping the future of treatment in 2026.

Advanced Ovarian Cancer Report Highlights

• The Advanced Ovarian Cancer companies and academics are working to assess challenges and seek opportunities that could influence Advanced Ovarian Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Advanced Ovarian Cancer.

Advanced Ovarian Cancer Emerging Drugs Analysis

This segment of the Advanced Ovarian Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Advanced Ovarian Cancer Emerging Drugs

Stenoparib: Allarity Therapeutics

Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and Tankyrase 1 and 2. At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the Wnt signaling pathway. Aberrant Wnt/β-catenin signaling has been implicated in the development and progression of numerous cancers. By inhibiting PARP and blocking Wnt pathway activation, stenoparib’s unique therapeutic action shows potential as a promising therapeutic. Allarity has exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. Some approved PARP inhibitors have recently been shown to be associated with less favorable survival outcomes than initially established. Allarity’s Phase II trial data for stenoparib to date shows that the drug has much less myelotoxicity than the FDA approved PARP inhibitors. Currently, the drug is in the Phase II stage of its development for the treatment of Advanced Ovarian Cancer. 

ATX-295: Accent Therapeutics

ATX-295 is an investigational small-molecule therapy developed by Accent Therapeutics for the treatment of solid tumors. It is a selective inhibitor of KIF18A, a mitotic kinesin protein essential for cell division in cancers with chromosomal instability. By targeting this pathway, ATX-295 induces mitotic arrest and tumor cell death while sparing normal cells. The drug is currently in Phase I/II clinical development, with studies evaluating its safety, tolerability, and preliminary anti-tumor activity across multiple cancer types.

Further product details are provided in the report……..

Advanced Ovarian Cancer Therapeutic Assessment

This segment of the report provides insights about the different Advanced Ovarian Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major  Players in Advanced Ovarian Cancer

• There are approx. 10+ key companies which are developing the therapies for Advanced Ovarian Cancer. The companies which have their Advanced Ovarian Cancer drug candidates in the most advanced stage, i.e. Phase II include, Allarity Therapeutics

DelveInsight’s report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

• Route of Administration

Advanced Ovarian Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as 

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

 

• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
  
  

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Advanced Ovarian Cancer Clinical Trails Activities 

The Advanced Ovarian Cancer Pipeline report provides insights Advanced Ovarian Cancer clinical trails within Phase III, II, I, preclinical and discovery stage. It also analyses Advanced Ovarian Cancer therapeutic drugs key players involved in developing key drugs. 

Advanced Ovarian Cancer Pipeline Development Activities

The Advanced Ovarian Cancer Pipeline report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced Ovarian Cancer drugs.

Advanced Ovarian Cancer Report Insights

• Advanced Ovarian Cancer Pipeline Analysis
• Advanced Ovarian Cancer Therapeutic Assessment
• Advanced Ovarian Cancer Unmet Needs
• Impact of Advanced Ovarian Cancer Drugs

Advanced Ovarian Cancer Report Assessment

• Advanced Ovarian Cancer Pipeline Product Profiles
• Advanced Ovarian Cancer Therapeutic Assessment
• Advanced Ovarian Cancer Pipeline Assessment
• Inactive Advanced Ovarian Cancer drugs assessment
• Advanced Ovarian Cancer Unmet Needs

Discover actionable insights into the Advanced Ovarian Cancer market trends, epidemiology trends, and forecast through 2036 to stay ahead in emerging therapies.

Key Questions Answered in the Advanced Ovarian Cancer Report

Current Treatment Scenario and Emerging Therapies:

• How many Advanced Ovarian Cancer companies are developing Advanced Ovarian Cancer drugs?
• How many Advanced Ovarian Cancer drugs are developed by each company?
• How many Advanced Ovarian Cancer emerging drugs are in mid-stage, and late-stage of development for the treatment of Advanced Ovarian Cancer?
• What are the Advanced Ovarian Cancer key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Advanced Ovarian Cancer therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Advanced Ovarian Cancer and their status?
• What are the Advanced Ovarian Cancer key designations that have been granted to the emerging drugs?

Key Players

• Allarity Therapeutics
• AP Biosciences, Inc./Tasly Biopharmaceuticals Co.
• A2 Biotherapeutics Inc.
• Accent Therapeutics
• Verismo Therapeutics

Key Products

• Stenoparib
• B1962
• A2B694
• ATX-295
• SynKIR-110

Explore comprehensive insights into Advanced Ovarian Cancer epidemiology trends, patient population forecasts, and growth opportunities through 2034 for strategic decision-making.